Karl J. Puttlitz

Array ( [id] => 18953672 [patent_doc_number] => 20240041999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => Therapeutic RNA for Treating Cancer [patent_app_type] => utility [patent_app_number] => 18/258343 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18258343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20213506 [patent_doc_number] => 12410148 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Antibody drug conjugates [patent_app_type] => utility [patent_app_number] => 17/553745 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 54163 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1037 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17553745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17837621 [patent_doc_number] => 20220274926 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => IMMUNOREGULATORY AGENTS [patent_app_type] => utility [patent_app_number] => 17/552517 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62981 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17552517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17702941 [patent_doc_number] => 20220202947 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => METHODS OF PREVENTING METHIONINE OXIDATION IN IMMUNOCONJUGATES [patent_app_type] => utility [patent_app_number] => 17/549327 [patent_app_country] => US [patent_app_date] => 2021-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18600 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17549327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18139528 [patent_doc_number] => 20230013364 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 [patent_app_type] => utility [patent_app_number] => 17/549586 [patent_app_country] => US [patent_app_date] => 2021-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 104118 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17549586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19049401 [patent_doc_number] => 20240091370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/038812 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41877 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18038812 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17687774 [patent_doc_number] => 20220195066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/546976 [patent_app_country] => US [patent_app_date] => 2021-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17546976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503538 [patent_doc_number] => 20220096640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 17/546706 [patent_app_country] => US [patent_app_date] => 2021-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17546706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18299626 [patent_doc_number] => 20230109312 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/545562 [patent_app_country] => US [patent_app_date] => 2021-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42408 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17545562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18921471 [patent_doc_number] => 20240024475 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => Antigen-Binding Protein Targeting CD70 and Use Thereof [patent_app_type] => utility [patent_app_number] => 18/255332 [patent_app_country] => US [patent_app_date] => 2021-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16021 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255332 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595696 [patent_doc_number] => 20220145270 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => Antibody Conjugates and Methods of Making and Using the Same [patent_app_type] => utility [patent_app_number] => 17/532797 [patent_app_country] => US [patent_app_date] => 2021-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36811 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17532797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18716557 [patent_doc_number] => 11793880 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-24 [patent_title] => Conjugates of quaternized tubulysin compounds [patent_app_type] => utility [patent_app_number] => 17/533002 [patent_app_country] => US [patent_app_date] => 2021-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 100565 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 486 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17533002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19675960 [patent_doc_number] => 12187810 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-07 [patent_title] => Glycoside dual-cleavage linkers for antibody-drug conjugates [patent_app_type] => utility [patent_app_number] => 17/531343 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 36 [patent_no_of_words] => 40843 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 291 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17531343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19089690 [patent_doc_number] => 11951109 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-09 [patent_title] => EZH2 inhibitors for treating lymphoma [patent_app_type] => utility [patent_app_number] => 17/526307 [patent_app_country] => US [patent_app_date] => 2021-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 10 [patent_no_of_words] => 21871 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 330 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17526307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17561793 [patent_doc_number] => 20220125942 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES TO TREAT FOLLICULAR LYMPHOMA [patent_app_type] => utility [patent_app_number] => 17/525780 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68544 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -78 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17525780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17733381 [patent_doc_number] => 20220218840 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO [patent_app_type] => utility [patent_app_number] => 17/525582 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56306 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17525582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18860326 [patent_doc_number] => 20230414760 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => PHARMACEUTICAL FORMULATION [patent_app_type] => utility [patent_app_number] => 18/252818 [patent_app_country] => US [patent_app_date] => 2021-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24787 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18252818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895356 [patent_doc_number] => 20240010841 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => LABELS COMPRISING DIBROMOPYRIDAZINEDIONES FOR IMMUNOASSAYS AND METHODS OF PRODUCTION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/255654 [patent_app_country] => US [patent_app_date] => 2021-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14561 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255654 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428832 [patent_doc_number] => 20220056540 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/522332 [patent_app_country] => US [patent_app_date] => 2021-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14478 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 478 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17522332 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861910 [patent_doc_number] => 20230416345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => NEW TYPE II COLLAGEN BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 18/036142 [patent_app_country] => US [patent_app_date] => 2021-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12951 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18036142 [rel_patent_id] =>[rel_patent_doc_number] =>)